Physician profile
David J Sewall
NPI 1336149111
$2,296.73
in general payments reported to CMS, 2019-2025
22 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $309 · 2021: $305 · 2022: $50.27 · 2023: $125 · 2024: $217 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $423.93 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $464.72 | 2019-2022 | |
| Amgen INC. | $370.50 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $313.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $195.55 | 2019-2020 | |
| Abbott Laboratories | $195.17 | 2019-2022 | |
| Edwards Lifesciences Corporation | $125.00 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.14 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $69.32 | 2019-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $60.70 | 2019-2024 | |
| Pfizer INC. | $50.14 | 2019-2020 | |
| Chiesi USA, INC. | $38.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.07 | 2019-2023 | |
| Medtronic Vascular, INC. | $35.47 | 2019-2020 | |
| Cardinal Health 200 LLC | $20.21 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $19.61 | 2019 | |
| Medtronic, INC. | $18.92 | 2023 | Linq II |
| Abiomed | $18.81 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.06 | 2023 | Inpefa |
| Cvrx, INC. | $18.00 | 2025 | Barostim Neo System |
| Shockwave Medical, INC | $15.44 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $15.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sewall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.